Characteristics of expedited programmes for cancer drug approval in China

Nat Rev Drug Discov. 2021 Jun;20(6):416. doi: 10.1038/d41573-021-00080-0.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • China
  • Drug Approval / statistics & numerical data*
  • Government Agencies / trends*
  • Humans
  • Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents